WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
Summary
WallachBeth Capital LLC announced the closing of a public offering for bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company specializing in noninvasive lung cancer detection. The offering generated aggregate gross proceeds of \$3.2 million, before agent fees and expenses. It comprised 4,000,000 shares of common stock, or pre-funded warrants in lieu thereof, priced at \$0.80 per share (\$0.793 per pre-funded warrant). Each pre-funded warrant is immediately exercisable for one common share. WallachBeth Capital served as the sole placement agent for this transaction, which was expected to close around June 18, 2026. The securities were offered under a Form S-1 registration statement (File No. 333-296764), declared effective by the SEC.
Key takeaway
For investors tracking biotechnology companies, this offering indicates bioAffinity Technologies secured \$3.2 million in capital. This funding could support its development of noninvasive lung cancer tests, potentially impacting its future valuation and operational runway. You should monitor their progress in clinical development and market adoption of their diagnostic solutions.
Key insights
bioAffinity Technologies secured \$3.2 million through a public offering, facilitated by WallachBeth Capital, to advance its biotechnology initiatives.
Method
A public offering involves filing a Form S-1 registration statement with the SEC, engaging a sole placement agent like WallachBeth Capital, and offering common stock or pre-funded warrants at a set price.
Topics
- Public Offering
- Biotechnology
- Capital Markets
- Lung Cancer Detection
- SEC Filings
- Pre-funded Warrants
Best for: Investor, Legal Professional, Executive
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.